Portage Biotech Stock (NASDAQ:PRTG)
Previous Close
$7.90
52W Range
$2.10 - $40.80
50D Avg
$5.13
200D Avg
$5.65
Market Cap
$6.88M
Avg Vol (3M)
$665.19K
Beta
99.48
Div Yield
-
PRTG Company Profile
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
PRTG Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CUE | Cue Biopharma, Inc. |
| BPMC | Blueprint Medicines Corporation |
| DAWN | Day One Biopharmaceuticals, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| FENC | Fennec Pharmaceuticals Inc. |
| JANX | Janux Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| ARVN | Arvinas, Inc. |
| KROS | Keros Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| HRMY | Harmony Biosciences Holdings, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |